JAMA,
Journal Year:
2018,
Volume and Issue:
320(11), P. 1151 - 1151
Published: Sept. 18, 2018
Importance
The
positron
emission
tomography
(PET)
tracer
[18F]flortaucipir
allows
in
vivo
quantification
of
paired
helical
filament
tau,
a
core
neuropathological
feature
Alzheimer
disease
(AD),
but
its
diagnostic
utility
is
unclear.
Objective
To
examine
the
discriminative
accuracy
for
AD
vs
non-AD
neurodegenerative
disorders.
Design,
Setting,
and
Participants
In
this
cross-sectional
study,
719
participants
were
recruited
from
3
dementia
centers
South
Korea,
Sweden,
United
States
between
June
2014
November
2017
(160
cognitively
normal
controls,
126
patients
with
mild
cognitive
impairment
[MCI],
whom
65.9%
amyloid-β
[Aβ]
positive
[ie,
MCI
due
to
AD],
179
dementia,
254
various
disorders).
Exposures
index
test
was
PET
standardized
uptake
value
ratio
(SUVR)
5
predefined
regions
interest
(ROIs).
Cut
points
tau
positivity
determined
using
mean
+2
SDs
observed
controls
Youden
Index
contrast
controls.
Main
Outcomes
Measures
reference
standard
clinical
diagnosis
at
specialized
memory
centers.
primary
analysis,
(ie,
sensitivity
specificity)
examined
all
secondary
analyses,
area
under
curve
(AUC)
SUVR
compared
established
magnetic
resonance
imaging
measures
(hippocampal
volumes
signature
whole-brain
cortical
thickness),
specificity
disorders
determined.
Results
Among
participants,
overall
(SD)
age
68.8
(9.2)
years
48.4%
male.
proportions
who
26.3%,
65.9%,
100%,
23.8%
among
MCI,
disorders,
respectively.
medial-basal
lateral
temporal
cortex
showed
89.9%
(95%
CI,
84.6%-93.9%)
90.6%
86.3%-93.9%)
threshold
based
on
(SUVR,
1.34),
96.8%
92.0%-99.1%)
87.9%
81.9%-92.4%)
Index–derived
cutoff
1.27)
distinguishing
AUCs
ROIs
higher
(AUC
range,
0.92-0.95)
volumetric
MRI
0.63-0.75;
ROIsP
<
.001).
Diagnostic
performance
lower
0.75-0.84).
Conclusions
Relevance
diagnoses
disorder
clinic,
able
discriminate
other
diseases.
potential
patient
care
require
further
research
clinically
more
representative
populations.
Alzheimer s & Dementia,
Journal Year:
2018,
Volume and Issue:
14(4), P. 535 - 562
Published: April 1, 2018
In
2011,
the
National
Institute
on
Aging
and
Alzheimer's
Association
created
separate
diagnostic
recommendations
for
preclinical,
mild
cognitive
impairment,
dementia
stages
of
disease.
Scientific
progress
in
interim
led
to
an
initiative
by
update
unify
2011
guidelines.
This
unifying
is
labeled
a
"research
framework"
because
its
intended
use
observational
interventional
research,
not
routine
clinical
care.
Research
Framework,
disease
(AD)
defined
underlying
pathologic
processes
that
can
be
documented
postmortem
examination
or
vivo
biomarkers.
The
diagnosis
based
consequences
(i.e.,
symptoms/signs)
this
research
framework,
which
shifts
definition
AD
living
people
from
syndromal
biological
construct.
framework
focuses
with
biomarkers
persons.
Biomarkers
are
grouped
into
those
β
amyloid
deposition,
tau,
neurodegeneration
[AT(N)].
ATN
classification
system
groups
different
(imaging
biofluids)
process
each
measures.
AT(N)
flexible
new
added
three
existing
groups,
biomarker
beyond
when
they
become
available.
We
focus
as
continuum,
staging
may
accomplished
using
continuous
However,
we
also
outline
two
categorical
schemes
severity
impairment:
scheme
traditional
categories
six-stage
numeric
scheme.
It
important
stress
seeks
create
common
language
investigators
generate
test
hypotheses
about
interactions
among
(denoted
biomarkers)
symptoms.
appreciate
concern
biomarker-based
has
potential
misused.
Therefore,
emphasize,
first,
it
premature
inappropriate
general
medical
practice.
Second,
should
used
restrict
alternative
approaches
hypothesis
testing
do
There
will
situations
where
available
requiring
them
would
counterproductive
specific
goals
(discussed
more
detail
later
document).
Thus,
considered
template
all
age-related
impairment
dementia;
rather,
applied
fit
purpose
study.
Importantly,
examined
diverse
populations.
Although
possible
β-amyloid
plaques
neurofibrillary
tau
deposits
causal
pathogenesis,
these
abnormal
protein
define
unique
neurodegenerative
disorders
lead
dementia.
envision
defining
construct
enable
accurate
characterization
understanding
sequence
events
associated
AD,
well
multifactorial
etiology
approach
precise
trials
pathways
targeted
appropriate
people.
Neurology,
Journal Year:
2016,
Volume and Issue:
87(5), P. 539 - 547
Published: July 2, 2016
Biomarkers
have
become
an
essential
component
of
Alzheimer
disease
(AD)
research
and
because
the
pervasiveness
AD
pathology
in
elderly,
same
biomarkers
are
used
cognitive
aging
research.
A
number
current
issues
suggest
that
unbiased
descriptive
classification
scheme
for
these
would
be
useful.
We
propose
"A/T/N"
system
which
7
major
divided
into
3
binary
categories
based
on
nature
pathophysiology
each
measures.
"A"
refers
to
value
a
β-amyloid
biomarker
(amyloid
PET
or
CSF
Aβ42);
"T,"
tau
(CSF
phospho
tau,
PET);
"N,"
neurodegeneration
neuronal
injury
([(18)F]-fluorodeoxyglucose-PET,
structural
MRI,
total
tau).
Each
category
is
rated
as
positive
negative.
An
individual
score
might
appear
A+/T+/N-,
A+/T-/N-,
etc.
The
A/T/N
includes
new
modality
PET.
It
agnostic
temporal
ordering
mechanisms
underlying
pathogenesis.
all
individuals
any
population
regardless
mix
findings
therefore
suited
studies
aging.
does
not
specify
labels
thus
diagnostic
system.
categorizing
multidomain
at
person
level
format
easy
understand
use.
Given
present
lack
consensus
among
specialists
terminology
across
clinically
normal
dementia
spectrum,
will
broadest
acceptance
if
it
independent
from
one
defined
scheme.
Physiological Reviews,
Journal Year:
2018,
Volume and Issue:
98(2), P. 813 - 880
Published: Feb. 28, 2018
Neuronal
cell
death
occurs
extensively
during
development
and
pathology,
where
it
is
especially
important
because
of
the
limited
capacity
adult
neurons
to
proliferate
or
be
replaced.
The
concept
used
simple
as
there
were
just
two
three
types,
so
we
had
work
out
which
type
was
involved
in
our
particular
pathology
then
block
it.
However,
now
know
that
are
at
least
a
dozen
ways
for
die,
blocking
mechanism
may
not
prevent
from
dying,
non-neuronal
cells
also
contribute
neuronal
death.
We
review
here
mechanisms
by
intrinsic
extrinsic
apoptosis,
oncosis,
necroptosis,
parthanatos,
ferroptosis,
sarmoptosis,
autophagic
death,
autosis,
autolysis,
paraptosis,
pyroptosis,
phagoptosis,
mitochondrial
permeability
transition.
next
explore
development,
those
induced
axotomy,
aberrant
cell-cycle
reentry,
glutamate
(excitoxicity
oxytosis),
loss
connected
neurons,
aggregated
proteins
unfolded
protein
response,
oxidants,
inflammation,
microglia.
reassess
forms
occur
stroke
Alzheimer’s
disease,
most
pathologies
involving
discuss
why
has
been
difficult
pinpoint
involved,
if
matters,
molecular
overlap
interplay
between
subroutines,
therapeutic
implications
these
multiple
overlapping
Alzheimer s & Dementia,
Journal Year:
2016,
Volume and Issue:
13(3), P. 205 - 216
Published: Sept. 30, 2016
Our
goal
was
to
develop
cut
points
for
amyloid
positron
emission
tomography
(PET),
tau
PET,
flouro-deoxyglucose
(FDG)
and
MRI
cortical
thickness.We
examined
five
methods
determining
points.The
reliable
worsening
method
produced
a
point
only
PET.
The
specificity,
sensitivity,
accuracy
of
cognitively
impaired
versus
young
clinically
normal
(CN)
labeled
the
most
people
abnormal
all
gave
similar
FDG
thickness.
Cut
defined
using
age-matched
CN
fewer
abnormal.In
future,
we
will
use
single
PET
(standardized
uptake
value
ratio,
1.42;
centiloid,
19)
based
on
method.
We
base
lenient
thickness
conservative
Frontiers in Neuroscience,
Journal Year:
2018,
Volume and Issue:
12
Published: Jan. 30, 2018
The
so-called
amyloid
hypothesis,
that
the
accumulation
and
deposition
of
oligomeric
or
fibrillar
β
(Aβ)
peptide
is
primary
cause
Alzheimer's
disease
(AD),
has
been
mainstream
concept
underlying
AD
research
for
over
20
years.
However,
all
attempts
to
develop
Aβ-targeting
drugs
treat
have
ended
in
failure.
Here,
we
review
recent
findings
indicating
main
factor
development
progression
tau,
not
Aβ,
describe
deficiencies
hypothesis
supported
emergence
this
idea.
Brain,
Journal Year:
2017,
Volume and Issue:
140(12), P. 3286 - 3300
Published: Sept. 5, 2017
Neuropathological
and
in
vivo
studies
have
revealed
a
tight
relationship
between
tau
pathology
cognitive
impairment
across
the
Alzheimer's
disease
spectrum.
However,
is
also
intimately
associated
with
neurodegeneration
amyloid
pathology.
The
aim
of
present
study
was
therefore
to
assess
whether
grey
matter
atrophy
contribute
pathology,
as
measured
18F-AV-1451-PET
imaging,
deficits
disease.
We
included
40
amyloid-positive
patients
meeting
criteria
for
mild
due
(n
=
5)
or
probable
dementia
35).
Twelve
additionally
fulfilled
diagnostic
posterior
cortical
eight
logopenic
variant
primary
progressive
aphasia.
All
participants
underwent
3
T
magnetic
resonance
(11C-PiB)
positron
emission
tomography
(18F-AV-1451)
tomography,
episodic
semantic
memory,
language,
executive
visuospatial
functions
assessment.
Raw
scores
were
converted
age-adjusted
Z-scores
(W-scores)
averaged
compute
composite
each
domain.
Independent
regressions
performed
18F-AV-1451
binding
domain,
we
used
Biological
Parametric
Mapping
toolbox
further
control
local
volumes,
11C-PiB
uptake,
both.
Partial
correlations
causal
mediation
analyses
(mediation
R
package)
then
brain
regions
showing
an
association
cognition
both
uptake
volume.
Our
results
showed
that
decreased
performance
domain
related
increased
specific
conforming
established
brain-behaviour
relationships
(i.e.
memory:
medial
temporal
lobe
angular
gyrus;
left
anterior
regions;
language:
superior
supramarginal
functions:
bilateral
frontoparietal
right
more
than
occipitotemporal
regions).
This
pattern
regional
associations
remained
essentially
unchanged—although
less
spatially
extended—when
volume
maps
added
covariates.
Mediation
direct
matter-mediated
effects
on
performance.
Together,
these
show
region-specific
manner
These
are
weakly
burden,
but
part
mediated
by
volumes.
suggests
may
lead
through
variety
mechanisms,
including,
not
restricted
to,
loss.
might
implications
future
therapeutic
trials
targeting
Alzheimer s & Dementia,
Journal Year:
2024,
Volume and Issue:
20(8), P. 5143 - 5169
Published: June 27, 2024
Abstract
The
National
Institute
on
Aging
and
the
Alzheimer's
Association
convened
three
separate
work
groups
in
2011
single
2012
2018
to
create
recommendations
for
diagnosis
characterization
of
disease
(AD).
present
document
updates
research
framework
response
several
recent
developments.
Defining
diseases
biologically,
rather
than
based
syndromic
presentation,
has
long
been
standard
many
areas
medicine
(e.g.,
oncology),
is
becoming
a
unifying
concept
common
all
neurodegenerative
diseases,
not
just
AD.
consistent
with
this
principle.
Our
intent
objective
criteria
staging
AD,
incorporating
advances
biomarkers,
serve
as
bridge
between
clinical
care.
These
are
intended
provide
step‐by‐step
practice
guidelines
workflow
or
specific
treatment
protocols,
but
general
principles
inform
AD
that
reflect
current
science.
Highlights
We
define
(AD)
be
biological
process
begins
appearance
neuropathologic
change
(ADNPC)
while
people
asymptomatic.
Progression
burden
leads
later
progression
symptoms.
Early‐changing
Core
1
biomarkers
(amyloid
positron
emission
tomography
[PET],
approved
cerebrospinal
fluid
accurate
plasma
[especially
phosphorylated
tau
217])
map
onto
either
amyloid
beta
tauopathy
pathway;
however,
these
presence
ADNPC
more
generally
(i.e.,
both
neuritic
plaques
tangles).
An
abnormal
biomarker
result
sufficient
establish
decision
making
throughout
continuum.
Later‐changing
2
(biofluid
PET)
can
prognostic
information,
when
abnormal,
will
increase
confidence
contributing
integrated
scheme
described
accommodates
fact
copathologies,
cognitive
reserve,
resistance
may
modify
relationships
stages.
Annual Review of Neuroscience,
Journal Year:
2017,
Volume and Issue:
40(1), P. 189 - 210
Published: July 25, 2017
A
pathway
from
the
natively
unfolded
microtubule-associated
protein
Tau
to
a
highly
structured
amyloid
fibril
underlies
human
Tauopathies.
This
ordered
assembly
causes
disease
and
represents
gain
of
toxic
function.
In
recent
years,
evidence
has
accumulated
suggest
that
inclusions
form
first
in
small
number
brain
cells,
where
they
propagate
other
regions,
resulting
neurodegeneration
disease.
Propagation
pathology
is
often
called
prion-like,
which
refers
capacity
an
assembled
induce
same
abnormal
conformation
kind,
initiating
self-amplifying
cascade.
addition,
prion-like
encompasses
release
aggregates
cells
their
uptake
by
neighboring
cells.
mice,
intracerebral
injection
induces
monomeric
Tau,
followed
its
spreading
distant
regions.
Conformational
differences
between
transgenic
mouse
vitro
recombinant
account
for
greater
seeding
potency
aggregates.
Short
fibrils
constitute
major
species
seed-competent
brains
mice.
The
existence
multiple
Tauopathies
with
distinct
morphologies
led
suggestion
different
molecular
conformers
(or
strains)
aggregated
exist.